森川 賢一

森川 賢一

助教/副医局長

学歴

1993年3月
愛知県私立東海高等学校卒業
1999年3月
昭和大学医学部卒業
2003年3月
昭和大学大学院医学研究科第二内科学講座医学博士課程修了

職経

1999年5月
昭和大学病院消化器内科 医師
2003年4月
昭和大学医学部第二内科 員外助教
2005年4月
(財)東京都医学研究機構東京都神経科学総合研究所 微生物学部門 流動研究員
2006年4月
国立感染症研究所ウイルス第二部 流動研究員 及び 財団法人ヒューマンサイエンス財団 流動研究員
2007年4月
昭和大学医学部第二内科 員外助教 及び 国立感染症研究所ウイルス第二部 協力研究員
2008年1月
昭和大学医学部内科学講座消化器内科学部門 助教 及び 国立感染症研究所ウイルス第二部 協力研究員
2009年8月
Lausanne大学医学部消化器内科 博士研究員
2012年4月
昭和大学医学部内科学講座消化器内科学部門 助教
2014年10月
北海道大学大学院医学研究科内科学講座 消化器内科学分野 助教
2015年4月
北海道大学病院消化器内科 助教
2018年4月
北海道大学大学院医学研究院内科学分野消化器内科学教室 助教

専門分野

消化器内科学、肝臓病学、ウイルス肝炎診断・治療

所属学会・資格

  • 日本内科学会 認定内科医
  • 日本消化器病学会 専門医・支部評議員
  • 日本肝臓学会 専門医・指導医・東部会評議員
  • 日本消化器内視鏡学会 専門医・指導医
  • 日本医師会 認定産業医
  • 日本ウイルス学会
  • ヨーロッパ肝臓学会国際会員

受賞歴

  • 2016年 第6回Hepatology Meeting in Japan 2016 最優秀演題賞
  • 2016年 第25回アジア太平洋肝臓病学会議年次総会(APASL2016)Presidential Award
  • 2014年 Liver Forum in Kyoto研究助成
  • 2014年 日本肝臓学会・冠アワード
  • 2008年 第44回日本肝臓学会総会会長奨励賞
  • 2007年 第4回大正富山アワード
  • 2007年 宮川庚子記念財団研究助成

研究費等

国立研究開発法人日本医療研究開発機構(AMED)
  • 肝炎等克服実用化研究事業 「肝炎ウイルスの感染複製増殖と病原性発現を阻止するための基盤的研究とその応用のための基盤的開発」 研究分担者(2019年度-2021年度)
  • B型肝炎創薬実用化等研究事業 「B型肝炎ウイルスの感染複製増殖機構の解明に関する研究」 研究分担者 (2017年度-2019年度)
  • 肝炎等克服実用化研究事業 「肝炎ウイルスの感染複製増殖と病原性発現を阻止するための基盤的研究」 研究分担者 (2016年度-2018年度)
厚生労働省科学研究費補助金
  • B型肝炎創薬実用化等研究事業 「B型肝炎ウイルスの感染複製機構の解明に関する研究」 研究分担者 (2012年度-2016年度)
  • 肝炎等克服実用化研究事業 「肝炎ウイルスの複製増殖および病原性発現機構と薬剤感受性の解析」 研究分担者 (2014年度-2015年度)
文部科学省科学研究費補助金
  • 基盤研究(B) 「肝硬変の組織学的進展・軽快を担う間質微小環境因子の包括的解析」 研究分担者(2019-2021年度)
  • 基盤研究(C) 「レポーターアッセイによる新規・大規模抗HBV薬スクリーニング系を用いた薬剤開発」 研究分担者(2019-2021年度)
  • 基盤研究(C) 「B型肝炎ウイルスcccDNA排除を目指した新規抗ウイルス治療の開発」 研究代表者(2017年度-2019年度)
  • 挑戦的萌芽研究 「生体高分子シミュレーションによる抗ウイルス薬耐性化仮想アッセイシステムの構築」 研究分担者(2016年度-2017年度)
  • 基盤研究(C) 「C末端欠損HBx遺伝子インテグレーションによる肝発癌・悪性化機構の検討」 研究分担者(2016年度-2018年度)
  • 基盤研究(B) 「肝硬変の組織病態を修復する新規細胞治療法の探索」 研究分担者(2016年度-2018年度)
  • 基盤研究(C) 「C型肝炎ウイルスの粒子形成・分泌機構の解明と関与する細胞性因子の解析」 研究代表者(2014年度-2016年度)
  • 若手研究(B) 「C型肝炎ウイルス感染におけるレセプターを含む細胞性因子の関与」 研究代表者(2008年度-2009年度)
  • 基盤研究(B) 「C型肝炎ウイルス培養系による感染増殖効率規定因子の解析と新規治療標的候補の探索」 研究分担者(2006年度-2008年度)
  • 若手研究(B) 「感染性C型肝炎ウイルス粒子の精製と性状の解析」 研究代表者(2006年度-2007年度)
  • 特定領域研究 「感染性C型肝炎ウイルス粒子による肝細胞への遺伝子デリバリーシステムの構築」 研究分担者(2006年度-2007年度)
  • 基盤研究(C) 「C型肝炎ウイルス新規感染培養系における、ウイルスadaptationの解析」 研究分担者(2006年度-2007年度)

論文(英文のみ)

  1. Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    J Gastroenterol. 2019 Feb 18. doi: 10.1007/s00535-019-01556-y. [Epub ahead of print] PMID: 30778716
  2. Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Nakamura A, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N.
    Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    PLoS One. 2018 Dec 21;13(12):e0209615. doi: 10.1371/journal.pone.0209615. eCollection 2018. PMID: 30576386
  3. Suda G, Nakai M, Sho T, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Umemura MOM, Kawagishi N, Baba M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment: A Case Report.
    Intern Med. 2018 Dec 18. doi: 10.2169/internalmedicine.2077-18. [Epub ahead of print] PMID: 30568153
  4. Sho T, Suda G, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Izumi T, Kawagishi N, Baba M, Nakai M, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
    Intern Med. 2018 Nov 19. doi: 10.2169/internalmedicine.1856-18. [Epub ahead of print] PMID: 30449808
  5. Morikawa K, Nakamura A, Shimazaki T, Sakamoto N.
    Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
    Drug Des Devel Ther. 2018 Sep 5;12:2749-2756. doi: 10.2147/DDDT.S133697. eCollection 2018. Review. PMID: 30233138
  6. Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, Suzuki K, Nakamura A, Umemura M, Izumi T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ohnishi S, Sakamoto N.
    L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.
    Hepatol Commun. 2018 Aug 6;2(8):906-918. doi: 10.1002/hep4.1207. eCollection 2018 Aug. PMID: 30094402
  7. Suda G, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Hasebe C, Abe M, Haga H, Ueno Y, Masakane I, Abe K, Takahashi A, Ohira H, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Kawakami A, Kumagai K, Terasita K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    J Gastroenterol. 2018 Jul 17. doi: 10.1007/s00535-018-1495-6. [Epub ahead of print] PMID: 30019127
  8. Cai C, Koch B, Morikawa K, Suda G, Sakamoto N, Rueschenbaum S, Akhras S, Dietz J, Hildt E, Zeuzem S, Welsch C, Lange CM.
    Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids.
    Front Immunol. 2018 Apr 12;9:723. doi: 10.3389/fimmu.2018.00723. eCollection 2018. PMID: 29706960
  9. Doi H, Hayashi E, Arai J, Tojo M, Morikawa K, Eguchi J, Ito T, Kanto T, Kaplan DE, Yoshida H.
    Enhanced B-cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia.
    J Gastroenterol Hepatol. 2018 Feb 10. doi: 10.1111/jgh.14123. [Epub ahead of print] PMID: 29427373
  10. Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
    Hepatol Res. 2018 Jun;48(7):529-538. doi: 10.1111/hepr.13056. Epub 2018 Feb 15. PMID: 29316051
  11. Suda G, Ogawa K, Morikawa K, Sakamoto N.
    Treatment of hepatitis C in special populations.
    J Gastroenterol. 2018 May;53(5):591-605. doi: 10.1007/s00535-017-1427-x. Epub 2018 Jan 3. Review. PMID: 29299684
  12. Nakai M, Ogawa K, Takeda R, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Sho T, Suda G, Morikawa K, Sakamoto N.
    Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.
    Hepatol Res. 2018 Feb;48(3): E311-E319. doi: 10.1111/hepr.12988. Epub 2017 Nov 3. PMID: 28984014
  13. Maehara O, Suda G, Natsuizaka M, Ohnishi S, Komatsu Y, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Shimazaki T, Kimura M, Asano A, Fujimoto Y, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Whelan KA, Nakagawa H, Nakagawa K, Takeda H, Sakamoto N.
    Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.
    Carcinogenesis. 2017 Oct 26;38(11):1073-1083. doi: 10.1093/carcin/bgx095. PMID: 28927233
  14. Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: a randomized controlled study.
    Hepatol Res. 2018 Feb;48(3):E146-E154. doi: 10.1111/hepr.12938. Epub 2017 Aug 10. PMID: 28722780
  15. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M, Sho T, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N.
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Dec;24(12):1098-1106. doi: 10.1111/jvh.12737. PMID: 28632923
  16. Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, Ogawa K, Chuma M, Meguro T, Nakamura M, Nagasaka A, Horimoto H, Yamamoto Y, Sakamoto N.
    A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
    Drugs R D. 2017 Sep;17(3):381-388. doi: 10.1007/s40268-017-0187-7. PMID: 28573606
  17. Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N.
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2018 Jan;53(1):119-128. doi:10.1007/s00535-017-1353-y. PMID:28560477
  18. Yoshikawa A, Terashita K, Morikawa K, Matsuda S, Yamamura T, Sarashina K, Nakano S, Kobayashi Y, Sogabe S, Takahashi K, Haba S, Oda H, Takahashi T, Miyagishima T, Sakamoto N.
    Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
    Clin J Gastroenterol. 2017 Jun; 10(3):270-273. doi: 10.1007/s12328-017-0742-3. PMID: 28447325
  19. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ito J, Nakai M, Sho T, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N.
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Nov;67(5):1106-1108. doi: 10.1016/j.jhep.2017.04.008. PMID: 28438688
  20. Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N; NORTE Study Group.
    Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    J Gastroenterol. 2017 Oct;52(10):1122-1129. doi: 10.1007/s00535-017-1328-z. PMID: 28315983
  21. Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K, Sakamoto N.
    Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
    J Clin Transl Hepatol. 2016 Dec 28; 4(4):320-327. doi: 10.14218/JCTH.2016.00032. Review. PMID: 28097101
  22. Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus infected patients with renal impairment.
    Hepatol Res. 2017 Oct; 47(11):1127-1136. doi: 10.1111/hepr.12851. PMID: 27943523
  23. Morikawa K, Shimazaki T, Takeda R, Izumi T, Umumura M, Sakamoto N.
    Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection.
    Ann Transl Med. 2016 Sep; 4(18): 337. Review. PMID: 27761441
  24. Tsukuda Y, Suda G, Tsunematsu S, Ito J, Sato F, Terashita K, Nakai M, Sho T, Maehara O, Shimazaki T, Kimura M, Morikawa K, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Sakamoto N.
    Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection.
    J Med Virol. 2017 May; 89(5): 857-866. doi: 10.1002/jmv.24692. PMID: 27664407
  25. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N.
    Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    J Med Virol. 2017 Feb; 89(2): 267-275. doi: 10.1002/jmv.24643. PMID: 27459003
  26. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Kamiyama T, Taketomi A, Sakamoto N.
    Combination of neutrophil-to-lymphocyte ratio and early des-gamma-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Hepatol Res. 2017 May; 47(6):533-541. doi: 10.1111/hepr.12775. PMID: 27423140
  27. Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
    Hepatol Res. 2016 Dec; 46(13): 1294-1303. doi: 10.1111/hepr.12685. PMID: 26896756
  28. Morikawa K, Suda G, Sakamoto N.
    Viral life cycle of hepatitis B virus: host factors and druggable targets.
    Hepatol Res. 2016 Aug; 46(9):871-7. doi: 10.1111/hepr.12650. Review. PMID: 26776362
  29. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Ymasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terasita T, Nakai M, Horimoto H, Sho T, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N.
    Efficacy and safety of daclatasvir and asnaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    J Gastroenterol. 2016 Jul; 51(7):733-40. doi: 10.1007/s00535-016-1162-8. PMID: 26768604
  30. Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N.
    A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
    Cancer Biol Ther. 2015; 16(10):1453-61. doi: 10.1080/15384047.2015.1070992. PMID: 26176896
  31. Hiraide A, Hiroishi K, Shimazaki T, Eguchi J, Ishii S, Morikawa K, Sakaki M, Doi H, Omori R, Kajiwara A, Hayashi E, Shiina M, Hirayama Y, Imawari M.
    Increased expression of immuno-inhibitory molecules on peripheral blood lymphocytes may suppress disease progression in autoimmune hepatitis.
    Hepatol Res. 2015 Nov; 45(11):1152-4. doi: 10.1111/hepr.12479. PMID: 25581267
  32. Tsunematsu S, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, Mitsuhashi T, Kamachi H, Yokoo H, Kakisaka T, Tsuruga Y, Orimo T, Wakayama K, Ito J, Sato F, Terashita K, Nakai M, Tsukuda Y, Sho T, Suda G, Morikawa K, Natsuizaka M, Nakanishi M, Ogawa K, Taketomi A, Matsuno Y, Sakamoto N.
    Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Abdom Imaging. 2015 Aug; 40(6):1492-9. doi: 10.1007/s00261-015-0352-9. PMID: 25579172
  33. Welsch C, Haselow K, Gouttenoire J, Schneider M, Morikawa K, Martinez Y, Susser S, Sarrazin C, Zeuzem S, Antes I, Moradpour D, Lange CM.
    Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β-induction by efficient MAVS cleavage.
    J Hepatol. 2015 Apr; 62(4):779-84. doi: 10.1016/j.jhep.2014.11.009. PMID: 25463536
  34. Lange CM, Gouttenoire J, Duong FH, Morikawa K, Heim MH, Moradpour D.
    Vitamin D Receptor and Jak-STAT Signaling Crosstalk Results in Calcitriol-Mediated Increase of Hepatocellular Response to IFN-α.
    J Immunol. 2014 Jun 15; 192(12):6037-44. doi: 10.4049/jimmunol.1302296. PMID: 24821973
  35. Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HT, Lange CM, Dill MT, Heim MH, Donze O, Penin F, Quadroni M, Moradpour D.
    Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease.
    Hepatology. 2014 Feb; 59(2):423-33. doi: 10.1002/hep.26671. PMID: 23929719
  36. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Mullhaupt B, Negro F, Semela D, Kutalik Z, Muller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group.
    Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development.
    PLoS One. 2013 May 29; 8(5):e64053. doi: 10.1371/journal.pone.0064053. PMID: 23734184
  37. Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T.
    Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Gastroenterology. 2013 Aug; 145(2):447-55. doi: 10.1053/j.gastro.2013.05.007. PMID: 23673355
  38. Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T.
    Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.
    J Virol. 2012 Oct; 86(19): 10805-20. doi: 10.1128/JVI.07235-11. PMID: 22787209
  39. Inokuchi M, Ito T, Nozawa H, Miyashita M, Morikawa K, Uchikoshi M, Shimozuma Y, Arai J, Shimazaki T, Hiroishi K, Imawari M.
    Lymphotropic Hepatitis C Virus Has an Interferon-Resistant Phenotype.
    J Viral Hepat. 2012 Apr; 19(4):254-62. doi: 10.1111/j.1365-2893.2011.01541.x. PMID: 22404723
  40. Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, Wakita T.
    Replication and infectivity of a novel genotype 1b hepatitis C virus clone.
    Microbiol Immunol. 2012 May; 56(5): 308-17. doi: 10.1111/j.1348-0421.2012.00437.x. PMID: 22320232
  41. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour JF, Gerlach TJ, Heim MH, Malinverni R, Mullhaupt B, Negro F, Moradpour D, Bochud PY; Swiss Hepatitis C Cohort Study Group.
    Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Hepatology. 2012 Apr; 55(4):1038-47. doi: 10.1002/hep.24787. PMID: 22095909
  42. Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, Suzuki T, Wakita T.
    Production and characterization of HCV particles from serum-free culture.
    Vaccine. 2011 Jun 24; 29(29-30):4821-8. doi: 10.1016/j.vaccine.2011.04.069. PMID: 21550372
  43. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D.
    Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
    J Viral Hepat. 2011 May; 18(5):305-15. doi: 10.1111/j.1365-2893.2011.01451.x. Review. PMID: 21470343
  44. Inokuchi M, Ito T, Uchikoshi M, Shimozuma Y, Morikawa K, Nozawa H, Shimazaki T, Hiroishi K, Miyakawa Y, Imawari M.
    Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C.
    J Med Virol. 2009 Apr; 81(4):619-27. doi: 10.1002/jmv.21388. PMID: 19235854
  45. Doi H, Hiroishi K, Shimazaki T, Eguchi J, Baba T, Ito T, Matsumura T, Nozawa H, Morikawa K, Ishii S, Hiraide A, Sakaki M, Imawari M.
    Magnitude of CD8 T-cell responses against hepatitis C virus and severity of hepatitis do not necessarily determine outcomes in acute hepatitis C virus infection.
    Hepatol Res. 2009 Mar; 39(3):256-65. doi: 10.1111/j.1872-034X.2008.00459.x. PMID: 19054151
  46. Akazawa D, Date T, Morikawa K, Murayama A, Omi N, Takahashi H, Nakamura N, Ishii K, Suzuki T, Mizokami M, Mochizuki H, Wakita T.
    Characterization of infectious hepatitis C virus from liver-derived cell lines.
    Biochem Biophys Res Commun. 2008 Dec 19; 377(3):747-51. doi: 10.1016/j.bbrc.2008.10.063. PMID: 18951878
  47. Ishii K, Murakami K, Hmwe SS, Zhang B, Li J, Shirakura M, Morikawa K, Suzuki R, Miyamura T, Wakita T, Suzuki T.
    -encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins.
    Biochem Biophys Res Commun. 2008 Jul 4; 371(3):446-50. doi: 10.1016/j.bbrc.2008.04.110. PMID: 18445476
  48. Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T.
    Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection.
    J Virol. 2008 Jun; 82(12):5715-24. doi: 10.1128/JVI.02530-07. PMID: 18367533
  49. Murayama A, Date T, Morikawa K, Akazawa D, Miyamoto M, Kaga M, Ishii K, Suzuki T, Kato T, Mizokami M, Wakita T.
    The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells.
    J Virol. 2007 Aug; 81(15):8030-40. PMID: 17522229
  50. Morikawa K, Zhao Z, Date T, Miyamoto M, Murayama A, Akazawa D, Tanabe J, Sone S, Wakita T.
    The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles.
    J Med Virol. 2007 Jun; 79(6):714-23. PMID: 17457918
  51. Date T, Miyamoto M, Kato T, Morikawa K, Murayama A, Akazawa D, Tanabe J, Sone S, Mizokami M, Wakita T.
    An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain.
    Hepatol Res. 2007 Jun; 37(6):433-43. PMID: 17437527
  52. Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H, Baumert TF, Dubuisson J, Wakita T.
    CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection.
    J Virol. 2007 May; 81(10):5036-45. PMID: 17329343
  53. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T.
    Cell culture and infection system for hepatitis C virus.
    Nat Protoc. 2006; 1(5):2334-9. PMID: 17406476
  54. Morikawa K, Ito T, Nozawa H, Inokuchi M, Uchikoshi M, Saito T, Mitamura K, Imawari M.
    Translational enhancement of HCV RNA genotype 1b by 3'-untranslated and envelope 2 protein-coding sequences.
    Virology. 2006 Feb 20; 345(2):404-15. PMID: 16289655
  55. Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K.
    Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Am J Gastroenterol. 2003 Jun; 98(6):1377-83. PMID: 12818284